Soligenix (SNGX) Cost of Revenue (2010 - 2024)
Soligenix's (SNGX) quarterly Cost of Revenue came in at $2342.0 in Q2 2024, down 98.73% YoY from $184021.0 in Q3 2023, and down 98.0% on a QoQ basis from $117029.0 in Q1 2024.
Soligenix (SNGX) Cost of Revenue (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 15 years of Cost of Revenue data on file, last reported at $2342.0 in Q2 2024.
- Quarterly Cost of Revenue fell 98.73% year-over-year to $2342.0 in Q2 2024, while the trailing twelve-month figure through Dec 2024 was $119371.0 (down 83.91% YoY) and the FY2024 annual result came in at $119371.0, down 83.91% from the prior year.
- Cost of Revenue retreated to $2342.0 in Q2 2024, from $117029.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $829506.0 in Q1 2020 to a low of $2342.0 in Q2 2024.
- A 5-year average of $220101.7 and a median of $188662.5 in 2022 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue surged 145.13% — and 2024, when it slumped 98.73%.
- Tracing SNGX's Cost of Revenue over 5 years: stood at $241464.0 in 2020, then declined by 2.39% to $235698.0 in 2021, then slumped by 42.36% to $135865.0 in 2022, then surged by 63.06% to $221546.0 in 2023, then tumbled by 98.94% to $2342.0 in 2024.
- The last three Cost of Revenue figures came in at $2342.0 (Q2 2024), $117029.0 (Q1 2024), and $221546.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 2,342.00 |
| Jun 30, 2024 | 2,342.00 |
| Mar 31, 2024 | 117,029.00 |
| Mar 31, 2024 | 117,029.00 |
| Dec 31, 2023 | 221,546.00 |
| Dec 31, 2023 | 221,546.00 |
| Sep 30, 2023 | 110,441.00 |
| Sep 30, 2023 | 110,441.00 |
| Jun 30, 2023 | 184,021.00 |
| Jun 30, 2023 | 184,021.00 |
| Mar 31, 2023 | 226,040.00 |
| Mar 31, 2023 | 226,040.00 |
| Dec 31, 2022 | 135,865.00 |
| Dec 31, 2022 | 135,865.00 |
| Sep 30, 2022 | 129,440.00 |
| Sep 30, 2022 | 129,440.00 |
| Jun 30, 2022 | 193,304.00 |
| Jun 30, 2022 | 193,304.00 |
| Mar 31, 2022 | 92,213.00 |
| Mar 31, 2022 | 92,213.00 |